These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35003311)

  • 21. Changes of hepatic proteome in bile duct ligated rats with hepatic fibrosis following treatment with Yin-Chen-Hao-Tang.
    Lee TY; Chang HH; Kuo JJ; Shen JJ
    Int J Mol Med; 2009 Apr; 23(4):477-84. PubMed ID: 19288023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Huangqin-Huanglian Decoction Protects Liver against Non-alcoholic Fatty Liver Disease in High Fat-diet Mice.
    Yang H; Wei D; Zhang Y; Jian W
    Endocr Metab Immune Disord Drug Targets; 2024; 24(6):691-708. PubMed ID: 37859322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
    Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
    J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Asperosaponin VI protects alcohol-induced hepatic steatosis and injury via regulating lipid metabolism and ER stress.
    Wei L; Luo H; Jin Y; Shu Y; Wen C; Qin T; Yang X; Ma L; Liu Y; You Y; Zhou C
    Phytomedicine; 2023 Dec; 121():155080. PubMed ID: 37757711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploration of the hepatoprotective chemical base of an orally administered herbal formulation (YCHT) in normal and CCl
    Tian X; Liu H; Qiao S; Yin H; Chen M; Hu P; Wang Y; Peng H; Liu F; Pan G; Huang C
    J Ethnopharmacol; 2019 May; 236():161-172. PubMed ID: 30802610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. UPLC-G2Si-HDMS untargeted metabolomics for identification of metabolic targets of Yin-Chen-Hao-Tang used as a therapeutic agent of dampness-heat jaundice syndrome.
    Sun H; Yang L; Li MX; Fang H; Zhang AH; Song Q; Liu XY; Su J; Yu MD; Makino T; Wang XJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1081-1082():41-50. PubMed ID: 29502028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPAR
    Huang P; Yang L; Liu Y; Jiang Y; Li Y; Chen Z; Song H; Zheng P
    Evid Based Complement Alternat Med; 2022; 2022():1124901. PubMed ID: 35035496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of differentially expressed miRNAs and key genes involved in the progression of alcoholic fatty liver disease using rat models.
    Zhang X; Song W; Zhang M; Song Y; Di Y; Chen B; Tian H; Yuan X; Jin S
    Clin Res Hepatol Gastroenterol; 2022 Dec; 46(10):102012. PubMed ID: 36030034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Herb medicine Yin-Chen-Hao-Tang ameliorates hepatic fibrosis in bile duct ligation rats.
    Lee TY; Chang HH; Chen JH; Hsueh ML; Kuo JJ
    J Ethnopharmacol; 2007 Jan; 109(2):318-24. PubMed ID: 16989967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploration of the hepatoprotective chemical base of an orally administered herbal formulation (YCHT) in normal and CCl
    Liu H; Chen M; Yin H; Hu P; Wang Y; Liu F; Tian X; Huang C
    J Ethnopharmacol; 2019 Jun; 237():81-91. PubMed ID: 30904705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic hexapeptide (PGPIPN) prevents and cures alcoholic fatty liver disease by affecting the expressions of genes related with lipid metabolism and oxidative stress.
    Qi N; Liu C; Yang H; Shi W; Wang S; Zhou Y; Wei C; Gu F; Qin Y
    Oncotarget; 2017 Oct; 8(50):88079-88093. PubMed ID: 29152143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Study on the Therapeutic Efficacy of San Zi Yang Qin Decoction for Non-Alcoholic Fatty Liver Disease and the Underlying Mechanism Based on Network Pharmacology.
    Li Y; Liu Y; Yang M; Wang Q; Zheng Y; Xu J; Zheng P; Song H
    Evid Based Complement Alternat Med; 2021; 2021():8819245. PubMed ID: 33505505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FBXL5 promotes lipid accumulation in alcoholic fatty liver disease by promoting the ubiquitination and degradation of TFEB.
    Zhang S; Ji B; Li J; Ji W; Yang C; Yang L
    Cell Signal; 2023 Dec; 112():110905. PubMed ID: 37743009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum metabolomics strategy for understanding the therapeutic effects of Yin-Chen-Hao-Tang against Yanghuang syndrome.
    Liu XY; Zhang AH; Fang H; Li MX; Song Q; Su J; Yu MD; Yang L; Wang XJ
    RSC Adv; 2018 Feb; 8(14):7403-7413. PubMed ID: 35539139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of Gut Microbiome Metabolites via Network Pharmacology Analysis in Treating Alcoholic Liver Disease.
    Oh KK; Choi YR; Gupta H; Ganesan R; Sharma SP; Won SM; Jeong JJ; Lee SB; Cha MG; Kwon GH; Kim DJ; Suk KT
    Curr Issues Mol Biol; 2022 Jul; 44(7):3253-3266. PubMed ID: 35877448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishment of an alcoholic fatty liver disease model in mice.
    Tan P; Liang H; Nie J; Diao Y; He Q; Hou B; Zhao T; Huang H; Li Y; Gao X; Zhou L; Liu Y
    Am J Drug Alcohol Abuse; 2017 Jan; 43(1):61-68. PubMed ID: 27739874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Formononetin promotes fatty acid β-oxidation to treat non-alcoholic steatohepatitis through SIRT1/PGC-1α/PPARα pathway.
    Liao J; Xie X; Wang N; Wang Y; Zhao J; Chen F; Qu F; Wen W; Miao J; Cui H
    Phytomedicine; 2024 Feb; 124():155285. PubMed ID: 38185065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the protective effect of ShengMai-Yin and Ganmaidazao decoction combination against type 2 diabetes mellitus with nonalcoholic fatty liver disease by network pharmacology and validation in KKAy mice.
    Li S; Qian Y; Xie R; Li Y; Jia Z; Zhang Z; Huang R; Tuo L; Quan Y; Yu Z; Liu J; Xiang M
    J Ethnopharmacol; 2019 Oct; 242():112029. PubMed ID: 31216433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice.
    de la Rosa Rodriguez MA; Sugahara G; Hooiveld GJEJ; Ishida Y; Tateno C; Kersten S
    BMC Genomics; 2018 Jun; 19(1):443. PubMed ID: 29879903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic urinary profiling of alcohol hepatotoxicity and intervention effects of Yin Chen Hao Tang in rats using ultra-performance liquid chromatography/electrospray ionization quadruple time-of-flight mass spectrometry.
    Wang X; Lv H; Sun H; Liu L; Yang B; Sun W; Wang P; Zhou D; Zhao L; Dou S; Zhang G; Cao H
    J Pharm Biomed Anal; 2008 Dec; 48(4):1161-8. PubMed ID: 18835123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.